Judge Tells Drugmaker Pradaxa Bleeding Lawsuits Will Stand

Share Article

The Pradaxa Resource Center is the Web’s largest source for information on Pradaxa research, side effects and legal news. Visit http://www.Pradaxa-lawsuits.org

Pradaxa Diagram
Anyone who has suffered internal bleeding or had a loved one affected by taking Pradaxa is encouraged to speak with a lawyer about their legal rights as soon as possible.

The Pradaxa Resource Center, a patient advocacy group, is alerting patients who have suffered internal bleeding after taking the drug Pradaxa that legal options are available after a federal judge recently ordered against efforts by the maker of the drug to dismiss injury claims.

Anyone who has suffered internal bleeding or had a loved one affected by taking Pradaxa is encouraged to speak with a lawyer about their legal rights as soon as possible.

Pradaxa is a popular blood thinning drug prescribed to prevent strokes and blood clots in patients with atrial fibrillation. Although it has only been on the market since October of 2010, Pradaxa sold over $1 billion in the year ending February, 2012, according to a Wall Street Journal report on April 24, 2012.

On December 7, 2011, however, the FDA warned patients that it was investigating the safety of Pradaxa after receiving more injury or death reports from the drug than expected. The Institute for Safe Medication Practices also reported on June 6, 2012 that Pradaxa led all other medications in 2011 for reports of death or bleeding.

Due to the number of Pradaxa lawsuits expected, lawyers filed a motion on May 30, 2012 requesting that all cases be moved to one central federal court. The case is known as MDL No. 2385 IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois. In the motion, lawyers state they expect as many as 500 Pradaxa lawsuits will be filed.

On July 25th, Judge David Herndon, who is overseeing many of the currently filed claims and is among the candidates to preside over the federal MDL court, issued an order (PDF) in which he denied an attempt by drug maker Boehringer Ingelheim to dismiss Pradaxa bleeding lawsuits. Although the manufacturer argued that the drug label warned of internal bleeding, Judge Herndon ruled that this did not address the risk of uncontrollable bleeding and the lack of a reversal agent.

The Pradaxa Resource Center applauds the decision as it will clear the path for other victims of Pradaxa bleeding to seek help for their injuries. However, anyone with questions about their rights should speak with a lawyer who has experience in this type of federal MDL litigation. The Pradaxa Resource center works only with lawyers who are already handling Pradaxa lawsuits.

For more information on the research, warnings, side effects and legal options relating to the drug Pradaxa, or to speak with a lawyer, visit http://www.Pradaxa-lawsuits.org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Schroeder
Visit website